Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E18.97 EPS (ttm)4.55 Insider Own0.10% Shs Outstand1.76B Perf Week-4.31%
Market Cap151.37B Forward P/E7.10 EPS next Y12.14 Insider Trans-5.17% Shs Float1.76B Perf Month-8.61%
Income6.91B PEG2.29 EPS next Q2.76 Inst Own70.80% Short Float0.69% Perf Quarter-10.30%
Sales36.23B P/S4.18 EPS this Y42.30% Inst Trans12.74% Short Ratio1.73 Perf Half Y18.66%
Book/sh8.93 P/B9.66 EPS next Y16.18% ROA7.10% Target Price109.81 Perf Year16.48%
Cash/sh3.44 P/C25.06 EPS next 5Y8.27% ROE-303.40% 52W Range62.55 - 101.28 Perf YTD-2.61%
Dividend4.72 P/FCF20.42 EPS past 5Y36.80% ROI21.20% 52W High-14.86% Beta0.70
Dividend %5.47% Quick Ratio0.70 Sales past 5Y10.80% Gross Margin73.30% 52W Low37.86% ATR1.83
Employees47000 Current Ratio0.90 Sales Q/Q26.30% Oper. Margin30.20% RSI (14)29.85 Volatility1.97% 2.19%
OptionableYes Debt/Eq5.94 EPS Q/Q-192.90% Profit Margin19.10% Rel Volume1.41 Prev Close85.91
ShortableYes LT Debt/Eq5.58 EarningsJul 31 BMO Payout98.80% Avg Volume7.03M Price86.23
Recom1.90 SMA20-5.09% SMA50-8.07% SMA200-3.32% Volume9,924,654 Change0.37%
Jun-23-20Upgrade Atlantic Equities Neutral → Overweight $115
Jun-09-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Upgrade Argus Hold → Buy $115
May-18-20Resumed BofA/Merrill Neutral $95
May-12-20Upgrade JP Morgan Neutral → Overweight $105
May-11-20Resumed Morgan Stanley Overweight $95
Apr-20-20Upgrade RBC Capital Mkts Sector Perform → Outperform $79 → $93
Mar-23-20Downgrade Societe Generale Buy → Hold
Feb-27-20Initiated Barclays Equal Weight $97
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Sector Perform $86
Dec-26-19Reiterated Cowen Outperform $90 → $98
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Mar-25-19Downgrade Argus Buy → Hold
Jan-23-19Initiated UBS Neutral $91
Sep-26-20 06:37AM  
Sep-24-20 07:53AM  
Sep-22-20 08:59AM  
Sep-21-20 05:45PM  
08:00AM  
Sep-18-20 01:13PM  
06:10AM  
06:04AM  
Sep-17-20 11:45AM  
10:00AM  
06:47AM  
Sep-16-20 08:00AM  
Sep-15-20 08:00PM  
04:53PM  
Sep-14-20 05:45PM  
08:00AM  
Sep-13-20 08:00PM  
02:43PM  
02:00PM  
Sep-12-20 08:30AM  
Sep-11-20 08:26PM  
11:30AM  
10:20AM  
09:39AM  
09:14AM  
06:40AM  
06:30AM  
Sep-10-20 01:52PM  
Sep-09-20 07:35PM  
01:52PM  
Sep-08-20 05:18PM  
Sep-07-20 12:36PM  
Sep-06-20 04:06AM  
Sep-04-20 01:41PM  
10:26AM  
10:08AM  
10:07AM  
07:50AM  
07:28AM  
07:15AM  
07:00AM  
Sep-03-20 08:00AM  
Sep-02-20 08:09AM  
Sep-01-20 04:13PM  
03:04PM  
10:28AM  
06:29AM  
Aug-31-20 11:45AM  
09:54AM  
Aug-30-20 11:30AM  
Aug-28-20 07:10AM  
Aug-26-20 01:42PM  
01:13PM  
11:55AM  
05:01AM  
Aug-25-20 02:42PM  
08:45AM  
08:38AM  
08:00AM  
06:30AM  
Aug-24-20 02:15PM  
Aug-23-20 07:00AM  
Aug-20-20 11:11AM  
Aug-19-20 07:02PM  
11:04AM  
10:42AM  
09:59AM  
Aug-18-20 07:41AM  
Aug-16-20 06:42AM  
Aug-14-20 11:45AM  
11:29AM  
Aug-13-20 07:17PM  
01:17PM  
09:14AM  
Aug-12-20 05:45PM  
03:44PM  
Aug-07-20 12:24PM  
11:58AM  
11:30AM  
Aug-06-20 01:42PM  
Aug-04-20 07:44PM  
06:34AM  
Aug-03-20 07:56AM  
07:30AM  
07:29AM  
07:00AM  
Aug-02-20 04:31PM  
09:07AM  
Jul-31-20 08:32PM  
04:33PM  
01:09PM  
12:44PM  
11:54AM  
10:31AM  
10:26AM  
10:19AM  
09:47AM  
09:05AM  
08:14AM  
07:54AM  
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALBAN CARLOSVice ChairmanJul 07Sale100.0053,3255,332,555114,899Jul 08 09:19 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsMay 12Sale90.0023,0242,072,21152,760May 12 05:44 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerMay 05Sale85.0019,4451,652,8250May 07 05:01 PM
Durkin Brian LVP, ControllerMar 30Buy69.0075051,75016,844Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 20Buy67.5080054,00016,094Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 18Buy68.182,200150,00515,294Mar 20 04:56 PM
RAPP EDWARD JDirectorMar 03Buy87.872,875252,6172,875Mar 04 05:14 PM